Cardiovascular Systems Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2013. For the quarter, the company has posted revenue of $32,337,000 against $25,309,000 a year ago. Loss from operations was $7,495,000 against $5,122,000 a year ago. Net loss was $8,658,000 or $0.32 basic and diluted per share against $5,767,000 or $0.28 basic and diluted per share a year ago. Adjusted LBITDA was $4,627,000 against $3,211,000 a year ago. Losses increased from the prior year primarily due to planned investments, including approximately $7.5 million of expenses related to coronary approval and market launch initiatives.

For the six months, the company has posted revenue of $62,103,000 against $48,602,000 a year ago. Loss from operations was $14,342,000 against $10,328,000 a year ago. Net loss was $15,950,000 or $0.61 basic and diluted per share against $10,977,000 or $0.53 basic and diluted per share a year ago. Adjusted LBITDA was $8,858,000 against $6,441,000 a year ago.

For the fiscal 2014 third quarter ending March 31, 2014, the company expects revenue growth of 25% to 30% over the third quarter of fiscal 2013, to a range of $33.0 million to $34.5 million; Gross profit as a percentage of revenues similar to the second quarter of fiscal 2014; and net loss in the range of $9.2 million to $10.1 million, or loss per common share ranging from $0.31 to $0.34, assuming 30.3 million average shares outstanding.